FLASCO Clinical Oncology Series: GI Update - 2025

Tampa, FL US

Overview:

Explore cutting-edge research and innovative treatment approaches in gastrointestinal cancers, including updates on clinical trials, novel therapies, and best practices for improving patient outcomes. This conference will offer opportunities to collaborate with GI cancer thought leaders, providing attendees with a deeper understanding of the challenges and future directions in GI cancer care. This comprehensive approach ensures that participants are equipped with the knowledge and tools necessary to enhance their clinical practice and improve patient care.

Learning Objectives:

  1. Review latest advances in biomarkers and treatment for locally advanced GE3 cancers
  2. Review latest advances in biomarkers and treatment for metastatic GEJ cancer
  3. Role of surgery in the neoadjuvant treatment of esophageal cancer
  4. Role of neoadjuvant therapy in early stage pancreatic cancer
  5. Updates in the literature for the management of Pancreatic cancer
  6. Different diagnostic criteria for HER2 in CRC
  7. Understand mechanism of resistance of KRAS targeting in CRC.
  8. Review role of locoregional therapy across the BCLC spectrum and how this fits into the multidisciplinary management of HCC
  9. Review potential and emerging locoregional and systemic therapy combination strategies
  10. Update on Systemic therapy for HCC
     
Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 6.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 6.00 credit.
Course opens: 
02/07/2025
Course expires: 
03/08/2025
Cost:
$0.00
Rating: 
0

8:00 9:00am Breakfast, Visit Exhibits & Networking

9:00 10:00am

UPPER GI Moderator: Ahmed Zakari, MD, AdventHealth Cancer Institute

9:05 9:25am Advances in Systemic Therapy for Gastroesophageal Cancers Mohamedtaki Tejani, MD AdventHealth Cancer Institute

9:25 9:45am Contemporary Surgical Management of Esophageal Cancer Gary Chmielewski, MD, FACS AdventHealth Cancer Institute

9:45 10:00am Upper GI Q&A Ahmed Zakari, MD, Mohamedtaki Tejani, MD & Gary Chmielewski, MD, FACS

10:00 10:30am Break, Visit Exhibits & Networking

10:30 11:30am PANCREATIC CANCER Moderator: Mohamedtaki Tejani, MD, AdventHealth

10:35 10:55am Perioperative Approaches in Early-Stage Pancreatic Cancer in 2024 Ibrahim Nassour, MD University of Florida

10:55 11:15am Systemic and Personalized Therapies in Pancreatic Cancer: 2024 Insights Jesus C Fabregas, MD Memorial Cancer Institute

11:15 11:30am Pancreatic Cancer Q&A Mohamedtaki Tejani, MD, Ibrahim Nassour, MD, & Jesus C Fabregas, MD

11:30 12:30am COLON CANCER Moderator: Tiago Biachi, MD, Moffitt Cancer Center

11:35 11:55am HER2 Targeted Therapy in CRC Tiago Biachi, MD Moffitt Cancer Center

11:55 12:15pm KRAS Targeted Therapy in CRC Hao Xie, MD Mayo Clinic

12:15 12:30pm Colon Cancer Q&A Tiago Biachi, MD & Hao Xie, MD 12:30

1:15pm Lunch, Visit Exhibits & Networking 

1:15 2:15pm HEPATOCELLULAR CANCER Moderator: Lindsay Thornton, MD UM Health Sylvester Comprehensive Cancer Center

1:20 1:40pm When to Choose Locoregional Therapy and When Two Therapies May Be Better Than One: Practical and Data Informed Approach Christopher Malone, MD Washington University

1:40 2:00pm Systemic Therapies for HCC: A Year in Review and Future Insights for the Community Oncologist Ahmed Zakari, MD AdventHealth

2:00 2:15pm Hepatocellular Cancer Q&A Lindsay Thornton, MD, Christopher Malone, MD, & Ahmed Zakari, MD

2:15 3:15pm CHOLANGIOCARCINOMA Moderator: Richard Kim, MD Moffitt Cancer Center

2:20 2:40pm Role of Immunotherapy and Combination Approaches in Advanced Cholangiocarcinoma Amit Mahipal, MD Case Western Reserve University

2:40 3:00pm Targeted Therapy and Biomarker-Driven Treatments in Cholangiocarcinoma Sunyoung Lee, MD, PhD MD Anderson Cancer Center

3:00 3:15pm Cholangiocarcinoma Q&A Richard Kim, MD, Amit Mahipal, MD & Sunyoung Lee, MD

3:15 4:15pm NEUROENDOCRINE TUMORS Moderator: Mintallah Haider, MD, Moffitt Cancer Center

3:20 3:40pm New Direction in PRRT Jonathan Strosberg, MD Moffitt Cancer Center

3:40 4:00pm High Grade NEC – Current Landscape Renuka Iyer, MD Roswell Park Comprehensive Cancer Center

4:00 4:15pm NeuroEndocrine Tumors Q&A Mintallah Haider, MD, Jonathan Strosberg, MD, & Renuka Iyer, MD

4:15pm Closing Comments and Adjourn

Westin Tampa Waterside
725 S Harbour Island Blvd
Tampa, FL 33602
United States

Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.

Planners

Ahmed Zakari, MD discloses speaker's bureau with Incyte, Taiho, and Astra Zeneca during the past 24 months.
*Horizon CME has mitigated and resolved all relevant financial relationships

Faculty


Ahmed Zakari, MD discloses speaker's bureau with Incyte, Taiho, and Astra Zeneca during the past 24 months.
Mohamedtaki Tejani, MD discloses speaker's bureau with Natera and advisory boards with BMS during the past 24 months.
Jesus C Fabregas, MD discloses advisory boards with Astra Zeneca, BMS,Bristol-Myers, and Ipsen during the past 24 months.
Mohamedtaki Tejani, MD discloses speaker's bureau with Natera and advisory boards with BMS during the past 24 months.
Tiago Biachi, MD discloses speaker's bureau with BMS, MSD, and AZ, advisory boards with Moderna Ipsen, and received funds from A2Bio during the past 24 months.
Hao Xie, MD discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.
Christopher Malone, MD discloses speaker's Bureau with Boston Scientific and advisory boards with AstraZeneca and contracted research with Boston Scientific during the past 24 months.
Richard Kim, MD discloses speaker's bureau with AstraZeneca and Advisory Boards with AstraZeneca, Exelixis, Ispen, Eisai, Roche ,and Pfizer during the past 24 months.
Jonathan Strosberg, MD discloses advisory boards with Exelixis and consulting fee's with Novartis and contracted research with ITM, Alphamedix,  Rayzebio during the past 24 months.
Renuka Iyer, MD discloses advisory boards with Boehringer, Ingelheim, Exelixis, Crinetics, and Contracted Research with Ipsen and NETRF during the past 24 months.

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

 

 

Available Credit

  • 6.00 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 6.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 6.00 credit.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above


Supported Phones & Tablets:

Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above